Innoviva Reports Third Quarter 2016 Financial Results
- Q3 2016 royalty revenue earned up 118% vs Q3 2015
-
Net income of
$15.0 million , or$0.14 per share, and adjusted earnings per share of$0.17 per share -
Appointed
Patrick G. LePore as a director ofInnoviva -
Management will host a conference call and webcast today at
5:00 p.m. EDT
Net income for the third quarter of 2016 was
"We are pleased with the additional progress that was made last quarter
in the on-going global launch of RELVAR®/BREO® ELLIPTA® and ANORO®
ELLIPTA®. According to IMS,
Recent Highlights
-
Expanded the Board of
Innoviva by nominatingPatrick G. LePore as an independent director.Mr. LePore was formerly Chief Executive Officer and Chairman ofPar Pharmaceuticals, Inc. and currently serves on the Board of Directors of PharMerica Corporation andAgeneBio, Inc. -
In the third quarter of 2016, net sales of RELVAR®/BREO®
ELLIPTA® reported by GSK were
$212.2 million , up 117% from$97.8 million in the third quarter of 2015, with$111.5 million net sales in theU.S. and$100.7 million from non-U.S. markets. -
In the third quarter of 2016, net sales of ANORO® ELLIPTA®
reported by GSK were
$71.2 million , up 118% from$32.7 million in the third quarter of 2015, with$47.6 million of sales generated in theU.S. and$23.6 million from non-U.S. markets.
Additional Financial Results for the Third Quarter of 2016
Total revenue for the third quarter of 2016 was
Operating expenses for the third quarter of 2016 were
Net income in the third quarter of 2016 was
Conference Call and Webcast Information
To participate in Innoviva's conference call at
Non-GAAP Financial Measures
To supplement the consolidated financial statements presented in
accordance with generally accepted accounting principles in
Adjusted EBITDA is determined by taking GAAP net income (loss) and
adding back interest expense (income), taxes, stock-based compensation
expense, depreciation expense and amortization of capitalized fees paid
to a related party.
Adjusted earnings per share is determined by taking Adjusted net income
(loss) and dividing the total by the fully diluted number of shares
outstanding used to calculate the GAAP diluted EPS. Adjusted net income
(loss) is determined by taking GAAP net income (loss) and adding back
stock-based compensation expense, depreciation expense and amortization
of capitalized fees paid to a related party,
Adjusted EBITDA, adjusted net income (loss) and adjusted earnings per
share should not be considered in isolation or as a substitute to net
income/loss, income/loss from operations, cash flows from operating
activities, earnings per share or any other measure of financial
performance presented in accordance with GAAP. Adjusted earnings per
share is not intended to represent cash flow per share and does not
represent a measure of liquidity or cash available for distribution. The
principal limitation of these non-GAAP financial measures is that it
excludes significant elements that are required by GAAP to be recorded
in Innoviva's consolidated financial statements. In addition, it is
subject to inherent limitations as it reflects the exercise of judgments
by management in determining these non-GAAP financial measures. In order
to compensate for these limitations, management of
About
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
Forward-Looking Statements
This press release contains certain "forward-looking" statements as that
term is defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements relating to goals, plans,
objectives and future events.
|
||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
|
|
|||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
(unaudited) | (unaudited) | |||||||||||||||
Revenue: | ||||||||||||||||
Royalty revenue from a related party, net | $ | 33,088 | $ | 13,341 | $ | 89,294 | $ | 30,449 | ||||||||
Revenue from collaborative arrangements from a related party | 221 | 221 | 663 | 664 | ||||||||||||
Total revenue (1) | 33,309 | 13,562 | 89,957 | 31,113 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development (2) | 286 | 547 | 1,048 | 1,897 | ||||||||||||
General and administrative (2) | 5,105 | 4,581 | 17,582 | 14,929 | ||||||||||||
Total operating expenses | 5,391 | 5,128 | 18,630 | 16,826 | ||||||||||||
Income from operations | 27,918 | 8,434 | 71,327 | 14,287 | ||||||||||||
Other income (expense), net | 56 | (45 | ) | 1,743 | 1,117 | |||||||||||
Interest income | 162 | 90 | 411 | 291 | ||||||||||||
Interest expense | (13,103 | ) | (13,063 | ) | (39,416 | ) | (38,756 | ) | ||||||||
Net income (loss) | $ | 15,033 | $ | (4,584 | ) | $ | 34,065 | $ | (23,061 | ) | ||||||
Basic earnings per share | $ | 0.14 | $ | (0.04 | ) | $ | 0.31 | $ | (0.20 | ) | ||||||
Diluted earnings per share | $ | 0.13 | $ | (0.04 | ) | $ | 0.31 | $ | (0.20 | ) | ||||||
Shares used in computing basic earnings per share | 109,282 | 115,787 | 111,128 | 115,381 | ||||||||||||
Shares used in computing diluted earnings per share | 121,993 | 115,787 | 111,583 | 115,381 | ||||||||||||
Cash dividend declared per common share | $ | - | $ | 0.25 | $ | - | $ | 0.75 |
(1) Revenue is comprised of the following (in thousands): | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
|
|
|||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
(unaudited) | (unaudited) | |||||||||||||||
Royalties from a related party | $ | 36,544 | $ | 16,796 | $ | 99,661 | $ | 40,816 | ||||||||
Amortization of capitalized fees paid to a related party | (3,456 | ) | (3,455 | ) | (10,367 | ) | (10,367 | ) | ||||||||
Royalty revenue | 33,088 | 13,341 | 89,294 | 30,449 | ||||||||||||
Strategic alliance - MABA program | 221 | 221 | 663 | 664 | ||||||||||||
Total revenue from a related party | $ | 33,309 | $ | 13,562 | $ | 89,957 | $ | 31,113 |
(2) Amounts include stock-based compensation expense as follows (in thousands): | ||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||
|
|
|||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||
(unaudited) | (unaudited) | |||||||||||
Research and development | $ | 143 | $ | 220 | $ | 490 | $ | 687 | ||||
General and administrative | 1,575 | 1,248 | 5,933 | 4,536 | ||||||||
Total stock-based compensation | $ | 1,718 | $ | 1,468 | $ | 6,423 | $ | 5,223 |
|
||||||||
Condensed Consolidated Balance Sheets | ||||||||
(in thousands) | ||||||||
|
|
|||||||
2016 | 2015 | |||||||
(unaudited) | (1) | |||||||
Assets | ||||||||
Cash, cash equivalents and marketable securities | $ | 148,966 | $ | 187,283 | ||||
Other current assets | 37,155 | 27,042 | ||||||
Property and equipment, net | 381 | 221 | ||||||
Capitalized fees paid to a related party, net | 184,000 | 194,368 | ||||||
Other assets | 40 | 18 | ||||||
Total assets | $ | 370,542 | $ | 408,932 | ||||
Liabilities and stockholders' deficit | ||||||||
Other current liabilities | $ | 3,882 | $ | 4,695 | ||||
Accrued interest payable | 6,606 | 7,911 | ||||||
Deferred revenue | 3,320 | 3,984 | ||||||
Convertible subordinated notes | 241,535 | 250,992 | ||||||
Non-recourse notes payable, due 2029 | 481,465 | 482,139 | ||||||
Other long-term liabilities | 1,598 | 1,856 | ||||||
Stockholders' deficit | (367,864 | ) | (342,645 | ) | ||||
Total liabilities and stockholders' deficit | $ | 370,542 | $ | 408,932 | ||||
(1) The selected consolidated balance sheet amounts at |
|
||||||||
Cash Flows Summary | ||||||||
(in thousands) | ||||||||
Nine Months Ended | ||||||||
|
||||||||
2016 | 2015 | |||||||
(unaudited) | ||||||||
Net cash provided by operating activities | $ | 39,898 | $ | 3,214 | ||||
Net cash provided by (used in) investing activities | (27,900 | ) | 59,880 | |||||
Net cash used in financing activities | (77,984 | ) | (81,148 | ) |
|
||||||||||||||
Reconciliation of GAAP to Non-GAAP Operating Results | ||||||||||||||
(in thousands) | ||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||
|
|
|||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||
(unaudited) | (unaudited) | |||||||||||||
Reconciliation from GAAP net income (loss) to adjusted EBITDA: | ||||||||||||||
GAAP net income (loss) | $ | 15,033 | $ | (4,584 | ) | $ | 34,065 | $ | (23,061 | ) | ||||
Non-GAAP adjustments: | ||||||||||||||
Interest expense (income), net | 12,941 | 12,973 | 39,005 | 38,465 | ||||||||||
Stock-based compensation | 1,718 | 1,468 | 6,423 | 5,223 | ||||||||||
Depreciation | 35 | 28 | 90 | 55 | ||||||||||
Amortization of capitalized fees paid to a related party | 3,456 | 3,455 | 10,367 | 10,367 | ||||||||||
Adjusted EBITDA | $ | 33,183 | $ | 13,340 | $ | 89,950 | $ | 31,049 |
|
||||||||||||||
Reconciliation of GAAP to Non-GAAP Operating Results | ||||||||||||||
(in thousands, except per share data) | ||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||
|
|
|||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||
(unaudited) | (unaudited) | |||||||||||||
Reconciliation from GAAP net income (loss) to adjusted net income (loss) for computing adjusted earnings per share: | ||||||||||||||
GAAP net income (loss) | $ | 15,033 | $ | (4,584 | ) | $ | 34,065 | $ | (23,061 | ) | ||||
Non-GAAP adjustments: | ||||||||||||||
Stock-based compensation | 1,718 | 1,468 | 6,423 | 5,223 | ||||||||||
Depreciation | 35 | 28 | 90 | 55 | ||||||||||
Amortization of capitalized fees paid to a related party | 3,456 | 3,455 | 10,367 | 10,367 | ||||||||||
Adjusted net income (loss) | $ | 20,242 | $ | 367 | $ | 50,945 | $ | (7,416 | ) | |||||
Adjusted earnings per share | $ | 0.17 | $ | 0.00 | $ | 0.46 | $ | (0.06 | ) | |||||
Shares used in computing diluted earnings per share | 121,993 | 115,787 | 111,583 | 115,381 |
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006718/en/
Eric d'Esparbes
Sr. Vice President and Chief
Financial Officer
650-238-9640
investor.relations@inva.com
Source:
News Provided by Acquire Media